Adaptive Biotechnologies Corporation reports company developments tied to immune-driven diagnostics and immune medicine. The commercial-stage biotechnology company applies a proprietary platform to translate adaptive immune system genetics into clinical products, with operating activity organized around Minimal Residual Disease (MRD) and Immune Medicine.
Recurring updates for ADPT include clonoSEQ MRD testing adoption, MRD revenue trends, pharma regulatory milestone revenue, operating expense guidance, and quarterly financial results. Company news also covers immune receptor and TCR-antigen data partnerships, autoimmune and cancer-related research applications, investor conference participation, and management commentary on the company’s diagnostic and drug-development collaborations.
Adaptive Biotechnologies (Nasdaq: ADPT) reported third-quarter 2026 revenue of $83.9 million, down from the same quarter a year earlier. Revenue fell 11%, but increased 39% excluding the Genentech agreement, which generated no revenue this quarter. Minimal residual disease (MRD) revenue rose 28% to $72.6 million, or 44% excluding milestones; clonoSEQ test volume increased 46% to 39,587. Immune Medicine revenue declined 70% to $11.3 million.
Net income was $2.8 million versus $9.5 million a year earlier. Adjusted EBITDA, a non-GAAP earnings measure, fell to $14.3 million from $28.0 million; free cash flow was $7.7 million. Adaptive raised its expected full-year MRD revenue range to $276 million–$286 million from $268 million–$278 million. Cash, cash equivalents and marketable securities totaled $400.2 million at September 30. Revenue was recognized from successful target-discovery data delivery, while the Immune Medicine separation process continued.
Adaptive Biotechnologies (ADPT) will report third-quarter 2026 financial results after market close on November 4, 2026.
Management will host a conference call webcast at 1:30 p.m. Pacific / 4:30 p.m. Eastern. Live audio will be available in the Investors section of the company website, with an archived replay available within 24 hours after the event.
Adaptive Biotechnologies (ADPT) highlighted a new multiple myeloma cure definition presented at the International Myeloma Society meeting.
The definition covers newly diagnosed and relapsed patients. It requires five years in complete remission without myeloma treatment, at least four negative measurable residual disease (MRD) assessments, and no positive MRD result between them. One assessment must occur at the five-year mark. Tests must use next-generation sequencing or next-generation flow at a sensitivity of 10⁻⁶, or one myeloma cell among one million cells. PET/CT or diffusion-weighted whole-body MRI must show no disease at the start and end of the period, with no positive scan in between if additional scans are performed. Adaptive’s clonoSEQ is an FDA-cleared sequencing-based MRD test for myeloma using bone marrow.
Adaptive Biotechnologies (ADPT) reports that updated National Comprehensive Cancer Network (NCCN) Guidelines for Multiple Myeloma now provide a dedicated framework for routine minimal (or measurable) residual disease (MRD) assessment, explicitly naming its clonoSEQ assay as an FDA-cleared option. The new MYEL‑E page on Principles of MRD Testing recommends bone marrow MRD assessment using next-generation sequencing with an FDA-approved assay such as clonoSEQ or multicolor flow cytometry.
The guidelines state that MRD sensitivity of 10⁻⁶ is preferred, with 10⁻⁵ as the minimum recommended level. Recommended MRD testing timepoints now include annual assessment during maintenance therapy and testing after later treatment lines, including after CAR T‑cell therapy, emphasizing longitudinal monitoring. The updates highlight that MRD negativity and sustained MRD negativity can inform treatment escalation, de‑escalation, and maintenance decisions, while rising MRD positivity may warrant closer monitoring and clinical evaluation.
Adaptive Biotechnologies (Nasdaq: ADPT) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. Management is scheduled for a fireside chat on Tuesday, September 15, 2026, at 1:50 p.m. PT / 4:50 p.m. ET. A live and archived webcast will be available in the Investors section of the company’s website. Adaptive Biotechnologies is a commercial-stage biotechnology company using its proprietary immune medicine platform to develop diagnostics and treatments across Minimal Residual Disease (MRD) and Immune Medicine business segments.
Adaptive Biotechnologies (Nasdaq: ADPT) reported second quarter 2026 revenue of $71.6 million, up 22% year over year (30% excluding the Genentech Agreement). Minimal Residual Disease (MRD) revenue rose 33% to $66.2 million and represented 92% of total revenue, supported by a 43% increase in clonoSEQ test volume to 36,111 tests.
Immune Medicine revenue declined 40% to $5.4 million, but increased 8% excluding Genentech-related revenue. Net loss was $39.9 million, or $16.2 million excluding the loss on extinguishment of the OrbiMed revenue interest liability, while Adjusted EBITDA loss narrowed to $0.7 million from $7.2 million. The company completed a $345 million zero-coupon convertible senior notes offering, repaid the OrbiMed Purchase Agreement, ended the quarter with $371.7 million in cash, cash equivalents and marketable securities, and announced plans to separate its MRD and Immune Medicine businesses. Full-year 2026 MRD revenue guidance was raised to $268–$278 million, and total operating expense guidance was updated to $350–$355 million.
Adaptive Biotechnologies (Nasdaq: ADPT) will report second quarter 2026 financial results after market close on July 29, 2026. Management will host a webcasted conference call at 1:30 p.m. PT / 4:30 p.m. ET.
The live and archived audio will be accessible via the company’s Investors website.
Adaptive Biotechnologies (Nasdaq: ADPT) priced an upsized private offering of $300 million 0% convertible senior notes due 2031 to qualified institutional buyers under Rule 144A. The notes, maturing July 1, 2031, carry an initial conversion price of about $24.11, a 40% premium to the $17.22 share price.
Estimated net proceeds of $290.8 million (up to $334.5 million with the option) are expected to be used for capped call transactions, a $25 million repurchase of 1,451,800 shares, repayment of the OrbiMed Purchase Agreement to enhance financial flexibility, and MRD-related and general corporate purposes.
Adaptive Biotechnologies (Nasdaq: ADPT) plans to separate its MRD and Immune Medicine businesses. The company is evaluating strategic and structural alternatives for Immune Medicine and expects to determine a preferred separation path by year-end 2026.
MRD has scaled into a profitable, category-leading diagnostics business with expanded reimbursement, strong clinical evidence, and the clonoSEQ platform. Immune Medicine has built a differentiated discovery platform using a large clinically linked immune receptor dataset and AI-driven discovery.
Adaptive Biotechnologies (Nasdaq: ADPT) plans a private offering of $250 million convertible senior notes due 2031, with an option for an additional $37.5 million, to qualified institutional buyers under Rule 144A.
According to Adaptive Biotechnologies, net proceeds will fund capped call transactions, repay the OrbiMed Purchase Agreement, support up to $25 million in share repurchases, and be used for general corporate purposes and MRD business initiatives.